ArticleFrontiers in immunology2026
Rapid complete remission after one cycle of isatuximab-based quadruplet regimen in 1q21-positive primary plasma cell leukemia: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy. Patients often present with a large number of circulating plasma cells and extramedullary organ involvement at an early stage of the disease, frequently accompanied by severe infections and organ dysfunction, resulting in a poor overall prognosis. Current treatment strategies for pPCL are largely extrapolated from intensive induction regimens used for multiple myeloma; however, therapeutic outcomes remain limited, particularly in patients with high-risk cytogenetic abnormalities and impaired immune function. Isatuximab, an anti-CD38 monoclonal antibody, has demonstrated favorable efficacy in patients with relapsed/refractory multiple myeloma, but clinical evidence supporting its use in pPCL is still lacking. Here, we report a critically ill, newly diagnosed patient with primary plasma cell leukemia harboring 1q21 gain and extensive malignant plasma cell infiltration in the pleural effusion, who achieved complete remission (CR) after one cycle of an isatuximab-based combination regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.